Broxmeyer H E, Sherry B, Cooper S, Ruscetti F W, Williams D E, Arosio P, Kwon B S, Cerami A
Department of Medicine (Hematology/Oncology), Indiana University School of Medicine, Indianapolis 46202.
J Immunol. 1991 Oct 15;147(8):2586-94.
The effects of recombinant murine macrophage inflammatory protein (MIP)-1 beta and MIP-2 on the suppressive activity of MIP-1 alpha were tested using colony formation by human and murine bone marrow burst-forming unit-erythroid (BFU-E), colony-forming unit-granulocyte erythroid macrophage, megakaryocyte (CFU-GEMM), and colony-forming unit-granulocyte macrophage (CFU-GM) progenitor cells. MIP-1 beta, but not MIP-2, when added with MIP-1 alpha to cells, blocked the suppressive effects of MIP-1 alpha on both human and murine BFU-E, CFU-GEMM, and CFU-GM colony formation. Similar results were observed regardless of the early acting cytokines used: human rGM-CSF plus human rIL-3, and two recently described potent cytokines, a genetically engineered human rGM-CSF/IL-3 fusion protein and MGF, a c-kit ligand. The more potent the stimuli, the greater the suppressive activity noted. Pulse treatment of hu bone marrow cells with MIP-1 alpha at 4 degrees C for 1 h was as effective in inhibiting colony formation as continuous exposure of cells to MIP-1 alpha, and the pulsing effect with MIP-1 alpha could not be overcome by subsequent exposure of cells to MIP-1 beta. Also, pulse exposure of cells to MIP-1 beta blocked the activity of subsequently added MIP-1 alpha. For specificity, the action of a nonrelated myelosuppressive factor H-ferritin, was compared. MIP-1 alpha and H-ferritin were shown to act on similar target populations of early BFU-E, CFU-GEMM, and CFU-GM. MIP-1 beta did not block the suppressive activity of H-ferritin. Also, hemin and an inactive recombinant human H-ferritin mutein counteracted the suppressive effects of the wildtype H-ferritin molecule, but did not block the suppressive effects of MIP-1 alpha. These results show that MIP-1 beta's ability to block the action of MIP-1 alpha is specific. In addition, the results suggest that MIP-1 alpha and MIP-beta can, through rapid action, modulate early myeloid progenitor cell proliferation.
利用人及小鼠骨髓红细胞爆式集落形成单位(BFU-E)、粒系-红系-巨噬系-巨核系集落形成单位(CFU-GEMM)和粒系-巨噬系集落形成单位(CFU-GM)祖细胞的集落形成,测试重组小鼠巨噬细胞炎性蛋白(MIP)-1β和MIP-2对MIP-1α抑制活性的影响。当MIP-1β而非MIP-2与MIP-1α一起添加到细胞中时,可阻断MIP-1α对人及小鼠BFU-E、CFU-GEMM和CFU-GM集落形成的抑制作用。无论使用何种早期作用细胞因子,结果均相似:人重组粒细胞-巨噬细胞集落刺激因子(rGM-CSF)加人重组白细胞介素-3(rIL-3),以及最近描述的两种强效细胞因子,一种基因工程化的人rGM-CSF/IL-3融合蛋白和MGF(一种c-kit配体)。刺激越强,观察到的抑制活性越大。在4℃下用MIP-1α对人骨髓细胞进行1小时的脉冲处理,在抑制集落形成方面与细胞持续暴露于MIP-1α一样有效,且随后细胞暴露于MIP-1β不能克服MIP-1α的脉冲效应。此外,细胞对MIP-1β的脉冲暴露可阻断随后添加的MIP-1α的活性。为了验证特异性,比较了一种无关的骨髓抑制因子H-铁蛋白的作用。结果显示MIP-1α和H-铁蛋白作用于早期BFU-E、CFU-GEMM和CFU-GM的相似靶细胞群体。MIP-1β不阻断H-铁蛋白的抑制活性。此外,血红素和一种无活性的重组人H-铁蛋白突变体可抵消野生型H-铁蛋白分子的抑制作用,但不阻断MIP-1α的抑制作用。这些结果表明MIP-1β阻断MIP-1α作用的能力具有特异性。此外,结果提示MIP-1α和MIP-β可通过快速作用调节早期髓系祖细胞增殖。